Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder

Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder

This research study tests whether GLYX-13 - an experimental drug that acts on a brain receptor called NMDA - can decrease symptoms of OCD within hours. This is not a treatment study. Results from this study will allow doctors and researchers to better understand if you and others with OCD may respond to a class of medications that target the NMDA brain receptor.

Inclusion Criteria for Patients with No medication Washout:

• Age 18-55
• Physically healthy and not currently pregnant
• Primary Diagnosis of OCD
• currently off all psychotropic medications and other drugs
• Able to provide informed consent

Exclusion Criteria for Patients with No Medication Washout:

• Psychiatric conditions that make participation unsafe (schizophrenia [either self or first degree relative e.g. siblings, parents], history of violence, severe depression, eating disorder, substance abuse in prior year[including nicotine], lifetime substance dependence disorder [except nicotine])
• Female patients who are either pregnant or nursing
• Enrolled in or planning to enroll in Cognitive Behavioral Therapy.
• Medical conditions that make participation unsafe (e.g., high blood pressure, head injury)
• Currently on medications that make participation unsafe
• History of allergy, sensitivity, or intolerance to N-methyl-D-aspartate receptor (NMDAR) ligands including ketamine, dextromethorphan, memantine, methadone, dextropropoxyphene, or ketobemidone.

Inclusion Criteria for Patients with Medication Washout:

• Age 18-55
• Physically healthy and not currently pregnant
• Primary Diagnosis of OCD
• Currently on adequate dose of medication for treatment of OCD, but have not achieved at least partial remission and able to handle a medication washout.
• Able to provide informed consent

Exclusion Criteria for Patients with Medication Washout:

• Psychiatric conditions that make participation unsafe (schizophrenia [either self or first degree relative e.g. siblings, parents], history of violence, severe depression, eating disorder, substance abuse in prior year[including nicotine], lifetime substance dependence disorder [except nicotine])
• Female patients who are either pregnant or nursing
• Enrolled in or planning to enroll in Cognitive-Behavioral Therapy.
• Patient judged unlikely to be able to tolerated a medication washout.
• Medical conditions that make participation unsafe (e.g., high blood pressure, head injury)
• Currently on medications that make participation unsafe
• History of allergy, sensitivity, or intolerance to N-methyl-D-aspartate receptor (NMDAR) ligands including ketamine, dextromethorphan, memantine, methadone, dextropropoxyphene, or ketobemidone.